Novel thiazolidinedione hybrids as cholinesterase inhibitors and targeting neuroblastoma: design, synthesis, in vitro and in silico biological evaluations
 
Yazarlar (5)
Dr. Öğr. Üyesi Gurbet Çelik Turgut Pamukkale Üniversitesi, Türkiye
Arş. Gör. Furkan Çakır Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Prof. Dr. Alaattin Şen Pamukkale Üniversitesi, Türkiye
Doç. Dr. Feyzi Sinan TOKALI Kafkas Üniversitesi, Türkiye
Doç. Dr. Halil Şenol Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Bioorganic Chemistry (Q1)
Dergi ISSN 0045-2068 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 09-2025
Cilt / Sayı / Sayfa 164 / 1 / 108869–0 DOI 10.1016/j.bioorg.2025.108869
Makale Linki https://doi.org/10.1016/j.bioorg.2025.108869
UAK Araştırma Alanları
Organik Kimya
Özet
In this study, a novel series of eleven 3,5-disubstituted thiazolidine-2,4-dione (TZD) derivatives were rationally designed and synthesized, incorporating tertiary amine moieties to enhance cholinesterase binding. The acetamide-linked TZD scaffold was selected for its potential dual functionality: cholinesterase inhibition and cytotoxicity against neuronal cells. All compounds were evaluated for their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), alongside cytotoxicity assays on SH-SY5Y cancerous neuroblastoma and HEK-293 healthy cells. Compound 7 showed the strongest AChE inhibition (IC50 = 17.87 μM and Ki = 19.48 μM), while compound 8 exhibited the most potent BChE inhibition (IC50 = 34.98 μM and Ki = 26.15 μM), showing better activity than reference inhibitors (IC50Tacrine = 53.81 μM and IC50Galantamine = 43.21 μM). Several …
Anahtar Kelimeler
AChE | BChE | Cholinesterase inhibition | Neurodegenerative disorders | SH-SY5Y